#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Three key immunological features of lentiviral infection are the lack of an effective immune response against the virus , susceptibility to opportunistic pathogens , and generalized immune activation .
2-1	16-21	Three	abstract[2]	new[2]	coref	2-9[4_2]
2-2	22-25	key	abstract[2]	new[2]	_	_
2-3	26-39	immunological	abstract[2]	new[2]	_	_
2-4	40-48	features	abstract[2]	new[2]	_	_
2-5	49-51	of	abstract[2]	new[2]	_	_
2-6	52-62	lentiviral	abstract[2]|event[3]	new[2]|new[3]	coref	6-2[29_3]
2-7	63-72	infection	abstract[2]|event[3]	new[2]|new[3]	_	_
2-8	73-76	are	_	_	_	_
2-9	77-80	the	abstract[4]|abstract[5]	giv[4]|giv[5]	coref	2-9[5_4]
2-10	81-85	lack	abstract[4]|abstract[5]	giv[4]|giv[5]	_	_
2-11	86-88	of	abstract[4]|abstract[5]	giv[4]|giv[5]	_	_
2-12	89-91	an	abstract[4]|abstract[5]|abstract[6]	giv[4]|giv[5]|new[6]	coref	4-24[20_6]
2-13	92-101	effective	abstract[4]|abstract[5]|abstract[6]	giv[4]|giv[5]|new[6]	_	_
2-14	102-108	immune	abstract[4]|abstract[5]|abstract[6]	giv[4]|giv[5]|new[6]	_	_
2-15	109-117	response	abstract[4]|abstract[5]|abstract[6]	giv[4]|giv[5]|new[6]	_	_
2-16	118-125	against	abstract[4]|abstract[5]|abstract[6]	giv[4]|giv[5]|new[6]	_	_
2-17	126-129	the	abstract[4]|abstract[5]|abstract[6]|abstract[7]	giv[4]|giv[5]|new[6]|new[7]	coref	6-10[0_7]
2-18	130-135	virus	abstract[4]|abstract[5]|abstract[6]|abstract[7]	giv[4]|giv[5]|new[6]|new[7]	_	_
2-19	136-137	,	abstract[5]	giv[5]	_	_
2-20	138-152	susceptibility	abstract[5]|abstract[8]	giv[5]|new[8]	coref	9-14[60_8]
2-21	153-155	to	abstract[5]|abstract[8]	giv[5]|new[8]	_	_
2-22	156-169	opportunistic	abstract[5]|abstract[8]|substance[9]	giv[5]|new[8]|new[9]	_	_
2-23	170-179	pathogens	abstract[5]|abstract[8]|substance[9]	giv[5]|new[8]|new[9]	_	_
2-24	180-181	,	abstract[5]	giv[5]	_	_
2-25	182-185	and	abstract[5]	giv[5]	_	_
2-26	186-197	generalized	abstract[5]|event[10]	giv[5]|new[10]	coref	4-15[17_10]
2-27	198-204	immune	abstract[5]|event[10]	giv[5]|new[10]	_	_
2-28	205-215	activation	abstract[5]|event[10]	giv[5]|new[10]	_	_
2-29	216-217	.	_	_	_	_

#Text=The underlying mechanisms that lead to these immunologic alterations are complex and interrelated .
3-1	218-221	The	abstract[11]	new[11]	_	_
3-2	222-232	underlying	abstract[11]	new[11]	_	_
3-3	233-243	mechanisms	abstract[11]	new[11]	_	_
3-4	244-248	that	abstract[11]	new[11]	_	_
3-5	249-253	lead	abstract[11]	new[11]	_	_
3-6	254-256	to	abstract[11]	new[11]	_	_
3-7	257-262	these	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-8	263-274	immunologic	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-9	275-286	alterations	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-10	287-290	are	_	_	_	_
3-11	291-298	complex	_	_	_	_
3-12	299-302	and	_	_	_	_
3-13	303-315	interrelated	_	_	_	_
3-14	316-317	.	_	_	_	_

#Text=Regulatory T cells ( Treg ) are thought to contribute to the control of excessive immune activation on one hand and suppression of the anti-viral response on the other hand .
4-1	318-328	Regulatory	object[14]	new[14]	coref	6-23[35_14]
4-2	329-330	T	person|object[14]	new|new[14]	coref	14-11
4-3	331-336	cells	object[14]	new[14]	_	_
4-4	337-338	(	_	_	_	_
4-5	339-343	Treg	abstract	new	coref	6-23
4-6	344-345	)	_	_	_	_
4-7	346-349	are	_	_	_	_
4-8	350-357	thought	_	_	_	_
4-9	358-360	to	_	_	_	_
4-10	361-371	contribute	_	_	_	_
4-11	372-374	to	_	_	_	_
4-12	375-378	the	abstract[16]	new[16]	_	_
4-13	379-386	control	abstract[16]	new[16]	_	_
4-14	387-389	of	abstract[16]	new[16]	_	_
4-15	390-399	excessive	abstract[16]|event[17]	new[16]|giv[17]	_	_
4-16	400-406	immune	abstract[16]|event[17]	new[16]|giv[17]	_	_
4-17	407-417	activation	abstract[16]|event[17]	new[16]|giv[17]	_	_
4-18	418-420	on	abstract[16]	new[16]	_	_
4-19	421-424	one	abstract[16]|object[18]	new[16]|new[18]	_	_
4-20	425-429	hand	abstract[16]|object[18]	new[16]|new[18]	_	_
4-21	430-433	and	_	_	_	_
4-22	434-445	suppression	event[19]	new[19]	coref	5-1[22_19]
4-23	446-448	of	event[19]	new[19]	_	_
4-24	449-452	the	event[19]|abstract[20]	new[19]|giv[20]	coref	7-29[50_20]
4-25	453-463	anti-viral	event[19]|abstract[20]	new[19]|giv[20]	_	_
4-26	464-472	response	event[19]|abstract[20]	new[19]|giv[20]	_	_
4-27	473-475	on	event[19]	new[19]	_	_
4-28	476-479	the	event[19]	new[19]	_	_
4-29	480-485	other	event[19]	new[19]	_	_
4-30	486-490	hand	event[19]	new[19]	_	_
4-31	491-492	.	_	_	_	_

#Text=Such Treg-mediated suppression can render the host immune system unable to clear chronic infections .
5-1	493-497	Such	event[22]	giv[22]	_	_
5-2	498-511	Treg-mediated	time|event[22]	new|giv[22]	_	_
5-3	512-523	suppression	event[22]	giv[22]	_	_
5-4	524-527	can	_	_	_	_
5-5	528-534	render	_	_	_	_
5-6	535-538	the	abstract[25]	new[25]	coref	9-9[59_25]
5-7	539-543	host	person|abstract[25]	new|new[25]	_	_
5-8	544-550	immune	organization|abstract[25]	new|new[25]	_	_
5-9	551-557	system	abstract[25]	new[25]	_	_
5-10	558-564	unable	_	_	_	_
5-11	565-567	to	_	_	_	_
5-12	568-573	clear	_	_	_	_
5-13	574-581	chronic	abstract[26]	new[26]	coref	9-16[61_26]
5-14	582-592	infections	abstract[26]	new[26]	_	_
5-15	593-594	.	_	_	_	_

#Text=During chronic human , simian , or feline immunodeficiency virus infection ( HIV-1 , SIV , and FIV , respectively ) , Treg cells are capable of suppressing antiviral responses in vitro .
6-1	595-601	During	_	_	_	_
6-2	602-609	chronic	event[29]	giv[29]	appos	6-13[31_29]
6-3	610-615	human	event[29]	giv[29]	_	_
6-4	616-617	,	event[29]	giv[29]	_	_
6-5	618-624	simian	event[29]	giv[29]	_	_
6-6	625-626	,	event[29]	giv[29]	_	_
6-7	627-629	or	event[29]	giv[29]	_	_
6-8	630-636	feline	event[29]	giv[29]	_	_
6-9	637-653	immunodeficiency	object|event[29]	new|giv[29]	_	_
6-10	654-659	virus	abstract|event[29]	giv|giv[29]	_	_
6-11	660-669	infection	event[29]	giv[29]	_	_
6-12	670-671	(	_	_	_	_
6-13	672-677	HIV-1	abstract|event[31]	new|giv[31]	coref	7-17[45_31]
6-14	678-679	,	event[31]	giv[31]	_	_
6-15	680-683	SIV	event[31]|abstract	giv[31]|new	_	_
6-16	684-685	,	event[31]	giv[31]	_	_
6-17	686-689	and	event[31]	giv[31]	_	_
6-18	690-693	FIV	event[31]|abstract[33]	giv[31]|new[33]	coref	7-18[0_33]
6-19	694-695	,	event[31]|abstract[33]	giv[31]|new[33]	_	_
6-20	696-708	respectively	event[31]|abstract[33]	giv[31]|new[33]	_	_
6-21	709-710	)	_	_	_	_
6-22	711-712	,	_	_	_	_
6-23	713-717	Treg	abstract|object[35]	giv|giv[35]	coref|coref	7-6|7-25[49_35]
6-24	718-723	cells	object[35]	giv[35]	_	_
6-25	724-727	are	_	_	_	_
6-26	728-735	capable	_	_	_	_
6-27	736-738	of	_	_	_	_
6-28	739-750	suppressing	_	_	_	_
6-29	751-760	antiviral	abstract[36]	new[36]	coref	7-9[42_36]
6-30	761-770	responses	abstract[36]	new[36]	_	_
6-31	771-773	in	_	_	_	_
6-32	774-779	vitro	organization	new	_	_
6-33	780-781	.	_	_	_	_

#Text=Our lab has shown that Treg suppression of antiviral responses is also exerted in vivo during chronic FIV infection and that transient depletion of CD25+ Treg cells improved the antiviral response .
7-1	782-785	Our	person|organization[39]	acc|new[39]	ana	10-1
7-2	786-789	lab	organization[39]	new[39]	_	_
7-3	790-793	has	_	_	_	_
7-4	794-799	shown	_	_	_	_
7-5	800-804	that	_	_	_	_
7-6	805-809	Treg	abstract|event[41]	giv|new[41]	coref	7-26
7-7	810-821	suppression	event[41]	new[41]	_	_
7-8	822-824	of	event[41]	new[41]	_	_
7-9	825-834	antiviral	event[41]|abstract[42]	new[41]|giv[42]	coref	8-13[55_42]
7-10	835-844	responses	event[41]|abstract[42]	new[41]|giv[42]	_	_
7-11	845-847	is	_	_	_	_
7-12	848-852	also	_	_	_	_
7-13	853-860	exerted	_	_	_	_
7-14	861-863	in	_	_	_	_
7-15	864-868	vivo	abstract	new	coref	18-5
7-16	869-875	during	_	_	_	_
7-17	876-883	chronic	event[45]	giv[45]	coref	8-9[54_45]
7-18	884-887	FIV	abstract|event[45]	giv|giv[45]	coref	10-20
7-19	888-897	infection	event[45]	giv[45]	_	_
7-20	898-901	and	_	_	_	_
7-21	902-906	that	_	_	_	_
7-22	907-916	transient	abstract[46]	new[46]	coref	18-5[164_46]
7-23	917-926	depletion	abstract[46]	new[46]	_	_
7-24	927-929	of	abstract[46]	new[46]	_	_
7-25	930-935	CD25+	abstract[46]|abstract|object[49]	new[46]|new|giv[49]	coref	8-1[52_49]
7-26	936-940	Treg	abstract[46]|abstract|object[49]	new[46]|giv|giv[49]	coref	8-1
7-27	941-946	cells	abstract[46]|object[49]	new[46]|giv[49]	_	_
7-28	947-955	improved	_	_	_	_
7-29	956-959	the	abstract[50]	giv[50]	coref	11-13[74_50]
7-30	960-969	antiviral	abstract[50]	giv[50]	_	_
7-31	970-978	response	abstract[50]	giv[50]	_	_
7-32	979-980	.	_	_	_	_

#Text=Treg cells thus contribute to viral persistence in lentiviral infection by suppressing adaptive immune responses .
8-1	981-985	Treg	abstract|object[52]	giv|giv[52]	coref|coref	9-4|12-20[84_52]
8-2	986-991	cells	object[52]	giv[52]	_	_
8-3	992-996	thus	_	_	_	_
8-4	997-1007	contribute	_	_	_	_
8-5	1008-1010	to	_	_	_	_
8-6	1011-1016	viral	abstract[53]	new[53]	_	_
8-7	1017-1028	persistence	abstract[53]	new[53]	_	_
8-8	1029-1031	in	abstract[53]	new[53]	_	_
8-9	1032-1042	lentiviral	abstract[53]|event[54]	new[53]|giv[54]	coref	14-40[117_54]
8-10	1043-1052	infection	abstract[53]|event[54]	new[53]|giv[54]	_	_
8-11	1053-1055	by	_	_	_	_
8-12	1056-1067	suppressing	_	_	_	_
8-13	1068-1076	adaptive	abstract[55]	giv[55]	_	_
8-14	1077-1083	immune	abstract[55]	giv[55]	_	_
8-15	1084-1093	responses	abstract[55]	giv[55]	_	_
8-16	1094-1095	.	_	_	_	_

#Text=The role of Treg in the suppression of the innate immune system and susceptibility to opportunistic infections has been much less studied .
9-1	1096-1099	The	abstract[56]	new[56]	coref	15-17[125_56]
9-2	1100-1104	role	abstract[56]	new[56]	_	_
9-3	1105-1107	of	abstract[56]	new[56]	_	_
9-4	1108-1112	Treg	abstract[56]|abstract	new[56]|giv	coref	17-11
9-5	1113-1115	in	abstract[56]	new[56]	_	_
9-6	1116-1119	the	abstract[56]|event[58]	new[56]|new[58]	_	_
9-7	1120-1131	suppression	abstract[56]|event[58]	new[56]|new[58]	_	_
9-8	1132-1134	of	abstract[56]|event[58]	new[56]|new[58]	_	_
9-9	1135-1138	the	abstract[56]|event[58]|abstract[59]	new[56]|new[58]|giv[59]	_	_
9-10	1139-1145	innate	abstract[56]|event[58]|abstract[59]	new[56]|new[58]|giv[59]	_	_
9-11	1146-1152	immune	abstract[56]|event[58]|abstract[59]	new[56]|new[58]|giv[59]	_	_
9-12	1153-1159	system	abstract[56]|event[58]|abstract[59]	new[56]|new[58]|giv[59]	_	_
9-13	1160-1163	and	abstract[56]	new[56]	_	_
9-14	1164-1178	susceptibility	abstract[56]|abstract[60]	new[56]|giv[60]	_	_
9-15	1179-1181	to	abstract[56]|abstract[60]	new[56]|giv[60]	_	_
9-16	1182-1195	opportunistic	abstract[56]|abstract[60]|abstract[61]	new[56]|giv[60]|giv[61]	_	_
9-17	1196-1206	infections	abstract[56]|abstract[60]|abstract[61]	new[56]|giv[60]|giv[61]	_	_
9-18	1207-1210	has	_	_	_	_
9-19	1211-1215	been	_	_	_	_
9-20	1216-1220	much	_	_	_	_
9-21	1221-1225	less	_	_	_	_
9-22	1226-1233	studied	_	_	_	_
9-23	1234-1235	.	_	_	_	_

#Text=We have employed the intracellular opportunistic pathogen Listeria monocytogenes ( Lm ) to probe the immune defects associated with FIV .
10-1	1236-1238	We	person	giv	ana	11-7
10-2	1239-1243	have	_	_	_	_
10-3	1244-1252	employed	_	_	_	_
10-4	1253-1256	the	abstract[63]|animal[64]	new[63]|new[64]	appos	10-9[0_63]
10-5	1257-1270	intracellular	abstract[63]|animal[64]	new[63]|new[64]	_	_
10-6	1271-1284	opportunistic	abstract[63]|animal[64]	new[63]|new[64]	_	_
10-7	1285-1293	pathogen	abstract[63]|animal[64]	new[63]|new[64]	_	_
10-8	1294-1302	Listeria	animal[64]	new[64]	_	_
10-9	1303-1316	monocytogenes	abstract	giv	appos	10-11
10-10	1317-1318	(	_	_	_	_
10-11	1319-1321	Lm	abstract	giv	coref	12-35
10-12	1322-1323	)	_	_	_	_
10-13	1324-1326	to	_	_	_	_
10-14	1327-1332	probe	_	_	_	_
10-15	1333-1336	the	abstract[67]	new[67]	_	_
10-16	1337-1343	immune	abstract[67]	new[67]	_	_
10-17	1344-1351	defects	abstract[67]	new[67]	_	_
10-18	1352-1362	associated	abstract[67]	new[67]	_	_
10-19	1363-1367	with	abstract[67]	new[67]	_	_
10-20	1368-1371	FIV	abstract[67]|abstract	new[67]|giv	_	_
10-21	1372-1373	.	_	_	_	_

#Text=Using this immune challenge model , we found that FIV-infected cats have an impaired innate response that fails to gain initial control of bacterial replication prior to the adaptive immune response .
11-1	1374-1379	Using	_	_	_	_
11-2	1380-1384	this	abstract[70]	new[70]	_	_
11-3	1385-1391	immune	abstract[69]|abstract[70]	new[69]|new[70]	coref	18-16[168_69]
11-4	1392-1401	challenge	abstract[69]|abstract[70]	new[69]|new[70]	_	_
11-5	1402-1407	model	abstract[70]	new[70]	_	_
11-6	1408-1409	,	_	_	_	_
11-7	1410-1412	we	person	giv	ana	12-1
11-8	1413-1418	found	_	_	_	_
11-9	1419-1423	that	_	_	_	_
11-10	1424-1436	FIV-infected	person|animal[73]	new|new[73]	coref	13-15[95_73]
11-11	1437-1441	cats	animal[73]	new[73]	_	_
11-12	1442-1446	have	_	_	_	_
11-13	1447-1449	an	abstract[74]	giv[74]	coref	11-28[77_74]
11-14	1450-1458	impaired	abstract[74]	giv[74]	_	_
11-15	1459-1465	innate	abstract[74]	giv[74]	_	_
11-16	1466-1474	response	abstract[74]	giv[74]	_	_
11-17	1475-1479	that	abstract[74]	giv[74]	_	_
11-18	1480-1485	fails	abstract[74]	giv[74]	_	_
11-19	1486-1488	to	abstract[74]	giv[74]	_	_
11-20	1489-1493	gain	abstract[74]	giv[74]	_	_
11-21	1494-1501	initial	abstract[74]|abstract[75]	giv[74]|new[75]	coref	14-3[0_75]
11-22	1502-1509	control	abstract[74]|abstract[75]	giv[74]|new[75]	_	_
11-23	1510-1512	of	abstract[74]|abstract[75]	giv[74]|new[75]	_	_
11-24	1513-1522	bacterial	abstract[74]|abstract[75]|abstract[76]	giv[74]|new[75]|new[76]	_	_
11-25	1523-1534	replication	abstract[74]|abstract[75]|abstract[76]	giv[74]|new[75]|new[76]	_	_
11-26	1535-1540	prior	_	_	_	_
11-27	1541-1543	to	_	_	_	_
11-28	1544-1547	the	abstract[77]	giv[77]	coref	13-27[99_77]
11-29	1548-1556	adaptive	abstract[77]	giv[77]	_	_
11-30	1557-1563	immune	abstract[77]	giv[77]	_	_
11-31	1564-1572	response	abstract[77]	giv[77]	_	_
11-32	1573-1574	.	_	_	_	_

#Text=We also showed that locally delivered interleukin 15 ( IL-15 ) , a cytokine known to activate and stimulate natural killer ( NK ) cells , significantly restored innate immune function as measured by Lm clearance .
12-1	1575-1577	We	person	giv	ana	17-1
12-2	1578-1582	also	_	_	_	_
12-3	1583-1589	showed	_	_	_	_
12-4	1590-1594	that	_	_	_	_
12-5	1595-1602	locally	abstract[79]	new[79]	appos	12-10[0_79]
12-6	1603-1612	delivered	abstract[79]	new[79]	_	_
12-7	1613-1624	interleukin	abstract[79]	new[79]	_	_
12-8	1625-1627	15	abstract[79]	new[79]	_	_
12-9	1628-1629	(	_	_	_	_
12-10	1630-1635	IL-15	abstract	giv	appos	12-13[81_0]
12-11	1636-1637	)	_	_	_	_
12-12	1638-1639	,	_	_	_	_
12-13	1640-1641	a	abstract[81]	giv[81]	_	_
12-14	1642-1650	cytokine	abstract[81]	giv[81]	_	_
12-15	1651-1656	known	abstract[81]	giv[81]	_	_
12-16	1657-1659	to	abstract[81]	giv[81]	_	_
12-17	1660-1668	activate	abstract[81]	giv[81]	_	_
12-18	1669-1672	and	abstract[81]	giv[81]	_	_
12-19	1673-1682	stimulate	abstract[81]	giv[81]	_	_
12-20	1683-1690	natural	abstract[81]|person[82]|object[84]	giv[81]|new[82]|giv[84]	coref	13-5[90_84]
12-21	1691-1697	killer	abstract[81]|person[82]|object[84]	giv[81]|new[82]|giv[84]	_	_
12-22	1698-1699	(	abstract[81]|object[84]	giv[81]|giv[84]	_	_
12-23	1700-1702	NK	abstract[81]|abstract|object[84]	giv[81]|new|giv[84]	coref	13-5
12-24	1703-1704	)	abstract[81]|object[84]	giv[81]|giv[84]	_	_
12-25	1705-1710	cells	abstract[81]|object[84]	giv[81]|giv[84]	_	_
12-26	1711-1712	,	_	_	_	_
12-27	1713-1726	significantly	_	_	_	_
12-28	1727-1735	restored	_	_	_	_
12-29	1736-1742	innate	abstract[85]	new[85]	coref	17-14[156_85]
12-30	1743-1749	immune	abstract[85]	new[85]	_	_
12-31	1750-1758	function	abstract[85]	new[85]	_	_
12-32	1759-1761	as	abstract[85]	new[85]	_	_
12-33	1762-1770	measured	abstract[85]	new[85]	_	_
12-34	1771-1773	by	abstract[85]	new[85]	_	_
12-35	1774-1776	Lm	abstract[85]|abstract|abstract[87]	new[85]|giv|new[87]	coref|coref	13-31|14-23[114_87]
12-36	1777-1786	clearance	abstract[85]|abstract[87]	new[85]|new[87]	_	_
12-37	1787-1788	.	_	_	_	_

#Text=Further investigation revealed that NK cells and NK T cells ( NKT ) from FIV-infected cats display heightened constitutive levels of proliferation and apoptosis , and a defective response to Lm compared to the NK/NKT cell response in specific-pathogen-free ( SPF ) control cats .
13-1	1789-1796	Further	abstract[88]	new[88]	_	_
13-2	1797-1810	investigation	abstract[88]	new[88]	_	_
13-3	1811-1819	revealed	_	_	_	_
13-4	1820-1824	that	_	_	_	_
13-5	1825-1827	NK	abstract|object[90]|object[91]	giv|giv[90]|giv[91]	coref|coref|coref	13-5[91_90]|13-8|13-8[93_91]
13-6	1828-1833	cells	object[90]|object[91]	giv[90]|giv[91]	_	_
13-7	1834-1837	and	object[91]	giv[91]	_	_
13-8	1838-1840	NK	object[91]|abstract|object[93]	giv[91]|giv|giv[93]	coref|coref	14-11[110_93]|15-4
13-9	1841-1842	T	object[91]|object[93]	giv[91]|giv[93]	_	_
13-10	1843-1848	cells	object[91]|object[93]	giv[91]|giv[93]	_	_
13-11	1849-1850	(	_	_	_	_
13-12	1851-1854	NKT	abstract	new	_	_
13-13	1855-1856	)	_	_	_	_
13-14	1857-1861	from	_	_	_	_
13-15	1862-1874	FIV-infected	animal[95]	giv[95]	coref	13-39[105_95]
13-16	1875-1879	cats	animal[95]	giv[95]	_	_
13-17	1880-1887	display	_	_	_	_
13-18	1888-1898	heightened	abstract[96]	new[96]	_	_
13-19	1899-1911	constitutive	abstract[96]	new[96]	_	_
13-20	1912-1918	levels	abstract[96]	new[96]	_	_
13-21	1919-1921	of	abstract[96]	new[96]	_	_
13-22	1922-1935	proliferation	abstract[96]|abstract	new[96]|new	_	_
13-23	1936-1939	and	abstract[96]	new[96]	_	_
13-24	1940-1949	apoptosis	abstract[96]|abstract	new[96]|new	_	_
13-25	1950-1951	,	_	_	_	_
13-26	1952-1955	and	_	_	_	_
13-27	1956-1957	a	abstract[99]	giv[99]	coref	13-34[103_99]
13-28	1958-1967	defective	abstract[99]	giv[99]	_	_
13-29	1968-1976	response	abstract[99]	giv[99]	_	_
13-30	1977-1979	to	abstract[99]	giv[99]	_	_
13-31	1980-1982	Lm	abstract[99]|abstract	giv[99]|giv	coref	14-6
13-32	1983-1991	compared	abstract[99]	giv[99]	_	_
13-33	1992-1994	to	abstract[99]	giv[99]	_	_
13-34	1995-1998	the	abstract[99]|abstract[103]	giv[99]|giv[103]	coref	14-16[113_103]
13-35	1999-2005	NK/NKT	abstract[99]|organization|abstract[103]	giv[99]|new|giv[103]	_	_
13-36	2006-2010	cell	abstract[99]|place|abstract[103]	giv[99]|new|giv[103]	coref	14-17[112_0]
13-37	2011-2019	response	abstract[99]|abstract[103]	giv[99]|giv[103]	_	_
13-38	2020-2022	in	abstract[99]|abstract[103]	giv[99]|giv[103]	_	_
13-39	2023-2045	specific-pathogen-free	abstract[99]|abstract[103]|animal[105]	giv[99]|giv[103]|giv[105]	coref	17-20[157_105]
13-40	2046-2047	(	abstract[99]|abstract[103]|animal[105]	giv[99]|giv[103]|giv[105]	_	_
13-41	2048-2051	SPF	abstract[99]|abstract[103]|abstract|animal[105]	giv[99]|giv[103]|new|giv[105]	_	_
13-42	2052-2053	)	abstract[99]|abstract[103]|animal[105]	giv[99]|giv[103]|giv[105]	_	_
13-43	2054-2061	control	abstract[99]|abstract[103]|animal[105]	giv[99]|giv[103]|giv[105]	_	_
13-44	2062-2066	cats	abstract[99]|abstract[103]|animal[105]	giv[99]|giv[103]|giv[105]	_	_
13-45	2067-2068	.	_	_	_	_

#Text=The early control mechanism of Lm does not rely on T cells ; however , a T cell response is required for bacterial clearance , as demonstrated by T cell-deficient mice that are able to control but not clear Lm infection .
14-1	2069-2072	The	abstract[107]	new[107]	_	_
14-2	2073-2078	early	abstract[107]	new[107]	_	_
14-3	2079-2086	control	abstract|abstract[107]	giv|new[107]	coref	15-21[127_0]
14-4	2087-2096	mechanism	abstract[107]	new[107]	_	_
14-5	2097-2099	of	abstract[107]	new[107]	_	_
14-6	2100-2102	Lm	abstract[107]|abstract	new[107]|giv	coref	14-40
14-7	2103-2107	does	_	_	_	_
14-8	2108-2111	not	_	_	_	_
14-9	2112-2116	rely	_	_	_	_
14-10	2117-2119	on	_	_	_	_
14-11	2120-2121	T	person|object[110]	giv|giv[110]	coref|coref	14-17|16-33[139_110]
14-12	2122-2127	cells	object[110]	giv[110]	_	_
14-13	2128-2129	;	_	_	_	_
14-14	2130-2137	however	_	_	_	_
14-15	2138-2139	,	_	_	_	_
14-16	2140-2141	a	abstract[113]	giv[113]	coref	18-23[170_113]
14-17	2142-2143	T	person|place[112]|abstract[113]	giv|giv[112]|giv[113]	coref	15-4[119_112]
14-18	2144-2148	cell	place[112]|abstract[113]	giv[112]|giv[113]	_	_
14-19	2149-2157	response	abstract[113]	giv[113]	_	_
14-20	2158-2160	is	_	_	_	_
14-21	2161-2169	required	_	_	_	_
14-22	2170-2173	for	_	_	_	_
14-23	2174-2183	bacterial	abstract[114]	giv[114]	coref	18-28[171_114]
14-24	2184-2193	clearance	abstract[114]	giv[114]	_	_
14-25	2194-2195	,	_	_	_	_
14-26	2196-2198	as	_	_	_	_
14-27	2199-2211	demonstrated	_	_	_	_
14-28	2212-2214	by	_	_	_	_
14-29	2215-2216	T	animal[115]	new[115]	coref	16-6[130_115]
14-30	2217-2231	cell-deficient	animal[115]	new[115]	_	_
14-31	2232-2236	mice	animal[115]	new[115]	_	_
14-32	2237-2241	that	animal[115]	new[115]	_	_
14-33	2242-2245	are	animal[115]	new[115]	_	_
14-34	2246-2250	able	animal[115]	new[115]	_	_
14-35	2251-2253	to	animal[115]	new[115]	_	_
14-36	2254-2261	control	animal[115]	new[115]	_	_
14-37	2262-2265	but	animal[115]	new[115]	_	_
14-38	2266-2269	not	animal[115]	new[115]	_	_
14-39	2270-2275	clear	animal[115]	new[115]	_	_
14-40	2276-2278	Lm	animal[115]|abstract|event[117]	new[115]|giv|giv[117]	coref|coref	15-21|16-14[134_117]
14-41	2279-2288	infection	animal[115]|event[117]	new[115]|giv[117]	_	_
14-42	2289-2290	.	_	_	_	_

#Text=It seems that NK cell production of interferon gamma after stimulation with IL-12 and IL-18 plays an important role in Lm control .
15-1	2291-2293	It	_	_	_	_
15-2	2294-2299	seems	_	_	_	_
15-3	2300-2304	that	_	_	_	_
15-4	2305-2307	NK	abstract|place[119]|event[120]	giv|giv[119]|new[120]	coref|coref	16-6|16-52[145_119]
15-5	2308-2312	cell	place[119]|event[120]	giv[119]|new[120]	_	_
15-6	2313-2323	production	event[120]	new[120]	_	_
15-7	2324-2326	of	event[120]	new[120]	_	_
15-8	2327-2337	interferon	event[120]|animal[121]	new[120]|new[121]	_	_
15-9	2338-2343	gamma	event[120]|animal[121]	new[120]|new[121]	_	_
15-10	2344-2349	after	event[120]	new[120]	_	_
15-11	2350-2361	stimulation	event[120]|event[122]	new[120]|new[122]	_	_
15-12	2362-2366	with	event[120]|event[122]	new[120]|new[122]	_	_
15-13	2367-2372	IL-12	event[120]|event[122]|abstract	new[120]|new[122]|new	_	_
15-14	2373-2376	and	event[120]|event[122]	new[120]|new[122]	_	_
15-15	2377-2382	IL-18	event[120]|event[122]|abstract	new[120]|new[122]|new	_	_
15-16	2383-2388	plays	_	_	_	_
15-17	2389-2391	an	abstract[125]	giv[125]	_	_
15-18	2392-2401	important	abstract[125]	giv[125]	_	_
15-19	2402-2406	role	abstract[125]	giv[125]	_	_
15-20	2407-2409	in	abstract[125]	giv[125]	_	_
15-21	2410-2412	Lm	abstract[125]|abstract|abstract[127]	giv[125]|giv|giv[127]	coref	16-15
15-22	2413-2420	control	abstract[125]|abstract[127]	giv[125]|giv[127]	_	_
15-23	2421-2422	.	_	_	_	_

#Text=Several studies have shown that NK cell-depleted mice and rats fail to control initial Lm infection , resulting in a higher bacterial burden , whereas in normal animals infected with Lm , NK cells are recruited from the blood to the spleen , liver , and/or lymph nodes , and increased NK cell activity is observed during the first days of Lm infection .
16-1	2423-2430	Several	abstract[128]	new[128]	_	_
16-2	2431-2438	studies	abstract[128]	new[128]	_	_
16-3	2439-2443	have	_	_	_	_
16-4	2444-2449	shown	_	_	_	_
16-5	2450-2454	that	_	_	_	_
16-6	2455-2457	NK	abstract|animal[130]|animal[131]	giv|giv[130]|giv[131]	coref|coref	16-6[131_130]|16-33
16-7	2458-2471	cell-depleted	animal[130]|animal[131]	giv[130]|giv[131]	_	_
16-8	2472-2476	mice	animal[130]|animal[131]	giv[130]|giv[131]	_	_
16-9	2477-2480	and	animal[131]	giv[131]	_	_
16-10	2481-2485	rats	animal[131]|animal	giv[131]|new	_	_
16-11	2486-2490	fail	_	_	_	_
16-12	2491-2493	to	_	_	_	_
16-13	2494-2501	control	_	_	_	_
16-14	2502-2509	initial	event[134]	giv[134]	coref	16-62[149_134]
16-15	2510-2512	Lm	abstract|event[134]	giv|giv[134]	coref	16-31
16-16	2513-2522	infection	event[134]	giv[134]	_	_
16-17	2523-2524	,	_	_	_	_
16-18	2525-2534	resulting	_	_	_	_
16-19	2535-2537	in	_	_	_	_
16-20	2538-2539	a	abstract[135]	new[135]	_	_
16-21	2540-2546	higher	abstract[135]	new[135]	_	_
16-22	2547-2556	bacterial	abstract[135]	new[135]	_	_
16-23	2557-2563	burden	abstract[135]	new[135]	_	_
16-24	2564-2565	,	_	_	_	_
16-25	2566-2573	whereas	_	_	_	_
16-26	2574-2576	in	_	_	_	_
16-27	2577-2583	normal	animal[136]	new[136]	_	_
16-28	2584-2591	animals	animal[136]	new[136]	_	_
16-29	2592-2600	infected	animal[136]	new[136]	_	_
16-30	2601-2605	with	animal[136]	new[136]	_	_
16-31	2606-2608	Lm	animal[136]|abstract	new[136]|giv	coref	16-62
16-32	2609-2610	,	_	_	_	_
16-33	2611-2613	NK	abstract|object[139]	giv|giv[139]	coref	16-52
16-34	2614-2619	cells	object[139]	giv[139]	_	_
16-35	2620-2623	are	_	_	_	_
16-36	2624-2633	recruited	_	_	_	_
16-37	2634-2638	from	_	_	_	_
16-38	2639-2642	the	substance[140]	new[140]	_	_
16-39	2643-2648	blood	substance[140]	new[140]	_	_
16-40	2649-2651	to	_	_	_	_
16-41	2652-2655	the	place[141]	new[141]	_	_
16-42	2656-2662	spleen	place[141]	new[141]	_	_
16-43	2663-2664	,	_	_	_	_
16-44	2665-2670	liver	object	new	_	_
16-45	2671-2672	,	_	_	_	_
16-46	2673-2679	and/or	_	_	_	_
16-47	2680-2685	lymph	object[143]	new[143]	_	_
16-48	2686-2691	nodes	object[143]	new[143]	_	_
16-49	2692-2693	,	_	_	_	_
16-50	2694-2697	and	_	_	_	_
16-51	2698-2707	increased	abstract[146]	new[146]	_	_
16-52	2708-2710	NK	abstract|place[145]|abstract[146]	giv|giv[145]|new[146]	coref|coref	17-16|17-16[155_145]
16-53	2711-2715	cell	place[145]|abstract[146]	giv[145]|new[146]	_	_
16-54	2716-2724	activity	abstract[146]	new[146]	_	_
16-55	2725-2727	is	_	_	_	_
16-56	2728-2736	observed	_	_	_	_
16-57	2737-2743	during	_	_	_	_
16-58	2744-2747	the	time[147]	new[147]	_	_
16-59	2748-2753	first	time[147]	new[147]	_	_
16-60	2754-2758	days	time[147]	new[147]	_	_
16-61	2759-2761	of	time[147]	new[147]	_	_
16-62	2762-2764	Lm	time[147]|abstract|event[149]	new[147]|giv|giv[149]	coref	17-28
16-63	2765-2774	infection	time[147]|event[149]	new[147]|giv[149]	_	_
16-64	2775-2776	.	_	_	_	_

#Text=Our objective in the present study was to determine whether Treg contribute to the impaired NK cell function in FIV-infected cats , and reduced capacity to clear Lm .
17-1	2777-2780	Our	person|abstract[151]	giv|new[151]	ana	18-1
17-2	2781-2790	objective	abstract[151]	new[151]	_	_
17-3	2791-2793	in	abstract[151]	new[151]	_	_
17-4	2794-2797	the	abstract[151]|abstract[152]	new[151]|new[152]	_	_
17-5	2798-2805	present	abstract[151]|abstract[152]	new[151]|new[152]	_	_
17-6	2806-2811	study	abstract[151]|abstract[152]	new[151]|new[152]	_	_
17-7	2812-2815	was	_	_	_	_
17-8	2816-2818	to	_	_	_	_
17-9	2819-2828	determine	_	_	_	_
17-10	2829-2836	whether	_	_	_	_
17-11	2837-2841	Treg	abstract	giv	coref	18-6
17-12	2842-2852	contribute	_	_	_	_
17-13	2853-2855	to	_	_	_	_
17-14	2856-2859	the	abstract[156]	giv[156]	_	_
17-15	2860-2868	impaired	abstract[156]	giv[156]	_	_
17-16	2869-2871	NK	abstract|place[155]|abstract[156]	giv|giv[155]|giv[156]	coref	18-6[163_155]
17-17	2872-2876	cell	place[155]|abstract[156]	giv[155]|giv[156]	_	_
17-18	2877-2885	function	abstract[156]	giv[156]	_	_
17-19	2886-2888	in	abstract[156]	giv[156]	_	_
17-20	2889-2901	FIV-infected	abstract[156]|animal[157]	giv[156]|giv[157]	_	_
17-21	2902-2906	cats	abstract[156]|animal[157]	giv[156]|giv[157]	_	_
17-22	2907-2908	,	_	_	_	_
17-23	2909-2912	and	_	_	_	_
17-24	2913-2920	reduced	abstract[158]	new[158]	_	_
17-25	2921-2929	capacity	abstract[158]	new[158]	_	_
17-26	2930-2932	to	abstract[158]	new[158]	_	_
17-27	2933-2938	clear	abstract[158]	new[158]	_	_
17-28	2939-2941	Lm	abstract[158]|abstract	new[158]|giv	coref	18-20
17-29	2942-2943	.	_	_	_	_

#Text=We hypothesized that in vivo Treg cell depletion using anti-feline CD25 monoclonal antibody prior to innate immune challenge with Lm would improve the innate immune response and the clearance of bacteria .
18-1	2944-2946	We	person	giv	_	_
18-2	2947-2959	hypothesized	_	_	_	_
18-3	2960-2964	that	_	_	_	_
18-4	2965-2967	in	_	_	_	_
18-5	2968-2972	vivo	abstract|abstract[164]	giv|giv[164]	_	_
18-6	2973-2977	Treg	abstract|place[163]|abstract[164]	giv|giv[163]|giv[164]	_	_
18-7	2978-2982	cell	place[163]|abstract[164]	giv[163]|giv[164]	_	_
18-8	2983-2992	depletion	abstract[164]	giv[164]	_	_
18-9	2993-2998	using	abstract[164]	giv[164]	_	_
18-10	2999-3010	anti-feline	abstract[164]|substance[167]	giv[164]|new[167]	_	_
18-11	3011-3015	CD25	abstract[164]|abstract|substance[167]	giv[164]|new|new[167]	_	_
18-12	3016-3026	monoclonal	abstract[164]|object|substance[167]	giv[164]|new|new[167]	_	_
18-13	3027-3035	antibody	abstract[164]|substance[167]	giv[164]|new[167]	_	_
18-14	3036-3041	prior	abstract[164]	giv[164]	_	_
18-15	3042-3044	to	abstract[164]	giv[164]	_	_
18-16	3045-3051	innate	abstract[164]|abstract[168]	giv[164]|giv[168]	_	_
18-17	3052-3058	immune	abstract[164]|abstract[168]	giv[164]|giv[168]	_	_
18-18	3059-3068	challenge	abstract[164]|abstract[168]	giv[164]|giv[168]	_	_
18-19	3069-3073	with	abstract[164]|abstract[168]	giv[164]|giv[168]	_	_
18-20	3074-3076	Lm	abstract[164]|abstract[168]|abstract	giv[164]|giv[168]|giv	_	_
18-21	3077-3082	would	_	_	_	_
18-22	3083-3090	improve	_	_	_	_
18-23	3091-3094	the	abstract[170]	giv[170]	_	_
18-24	3095-3101	innate	abstract[170]	giv[170]	_	_
18-25	3102-3108	immune	abstract[170]	giv[170]	_	_
18-26	3109-3117	response	abstract[170]	giv[170]	_	_
18-27	3118-3121	and	_	_	_	_
18-28	3122-3125	the	abstract[171]	giv[171]	_	_
18-29	3126-3135	clearance	abstract[171]	giv[171]	_	_
18-30	3136-3138	of	abstract[171]	giv[171]	_	_
18-31	3139-3147	bacteria	abstract[171]|animal	giv[171]|new	_	_
18-32	3148-3149	.	_	_	_	_
